



Getting psyched for healthcare: Global event to connect businesses and investors to unlock commercial potential of psychedelics

-  *First edition of PSYCH Investor Summit: Europe & Asia to connect psychedelics healthcare businesses with leading European and APAC investors and funds.*
-  *Keynote presentation by Professor David Nutt, Director of Neuropsychopharmacology at Imperial College London, and other renowned industry experts will share key insights to promote the potential of psychedelics in mainstream medicine.*

16th April 2021, London - [PSYCH](#), the premier market intelligence and events firm that aims to unlock the potential of psychedelics in healthcare, is launching the [PSYCH Investor Summit: Europe & Asia](#). The virtual event, powered by industry-leaders in cannabis and psychedelics data intelligence [Prohibition Partners](#), aims to promote the potential of psychedelics in the healthcare industry and provide businesses the opportunity to showcase their projects directly to European and APAC investors and funds.

In light of the ongoing COVID-19 pandemic, the importance of mental health is increasingly in the spotlight, and as consumers look for new options to improve their mental health, the growing significance of the potential of psychedelics is pushing the healthcare industry to respond with solutions. The global psychedelics industry is expected to be worth over US\$100 billion, and as attitudes towards psychedelics shift dramatically, we are witnessing an international rise in clinical trials, academic research and commercial investment.

The PSYCH Investor Summit: Europe & Asia, taking place on the 21st April, will examine how new therapies are tackling the mental health pandemic, why microdosing is set to disrupt the mainstream and how legislation is expected to develop in seminal markets. Participants will also have the opportunity to engage with distinguished industry leaders, rising entrepreneurs and global psychedelics investors to share insights and help push forward this increasingly relevant industry.

According to PSYCH co-founder Stephen Murphy, *“The heightened focus on finding better solutions for mental health conditions that psychedelics can treat, combined with a wave of ongoing research that is coming to fruition, is leading to rapid rates of acceptance in mainstream medicine and increased investor interest. As an industry backed by science with the potential to revolutionise healthcare, PSYCH's purpose is to contribute to the advancement of this emerging frontier, while supporting the growth of businesses and giving them the opportunity to achieve global recognition for their groundbreaking accomplishments.”*

Following on from the success of previous Prohibition Partners virtual events in 2020, which saw over 2,500 delegates attend to hear from over 270 speakers, the PSYCH keynote speech will be given by renowned Professor David Nutt, Director of Neuropsychopharmacology, Imperial College London, and Head of Research, Awakn Life Sciences, who will guide the audience through the exciting developments within the industry and the pioneering research being carried out across Psychedelic Medicine in Europe.

Other industry experts speaking at the event include Ronan Levy, Co-Founder & Executive Chairman, [Field Trip Health Ltd.](#); Anthony Tennyson, CEO of [Awakn Life Sciences](#); Richard Cheung, General Counsel at [Noetic Fund](#); Tim Schlidt, Partner at [Palo Santo](#); Victoria Dekker, Head of Growth at [PSYCH](#); Peter Reitano, CEO of [Gwella](#); Nick Murray, Co-Founder & CEO of [Wake Network](#); Yeji Jesse Lee, Journalist for [Business Insider](#); Greg Kubin, Founder & Host of [Business Trip](#); and Conor O'Brien, Industry & Data Analyst for [Prohibition Partners](#).

With the aim of facilitating investment channels, the promoted companies will present to an audience of investors in 10-minute pitch slots followed by a 10-minute Q&A session, and will have the opportunity to be directly introduced to companies and individuals actively looking to invest.

- **Awakn Life Sciences** - Specialises in the integration of psychedelic medicine into mainstream healthcare to enable better mental health for more people through research, clinics and ecosystems.
- **Field Trip** - Aims to bring the world to life through psychedelics and psychedelic-enhanced therapies.
- **Gwella** - Making mushrooms for modern life, its mission is to build the most accessible and original over-the-counter portfolio of functional and psychedelic mushroom products that amplify individual and community wellness.
- **Wake Network** - Wake is advancing the field of fungi biosciences and is developing a personalized, genetics-based approach to therapeutics and wellness.

Partners will also be included in the [PSYCH: The Psychedelics as Medicine Report](#), currently in its second edition. The report profiles most major psychedelic substances — both naturally derived entheogens and synthetically manufactured psychedelics — and outlines the current state of worldwide regulatory frameworks, clinical trials, and commercial opportunities associated with these compounds.

-ENDS-

ABOUT PSYCH:

The leading global source for psychedelics market intelligence, PSYCH empowers operators, regulators and investors to make informed decisions. Our work intersects knowledge and networks, providing access to trustworthy data, independent sector analysis and engaging events. Powered by Prohibition Partners, the definitive source of data intelligence and strategy for the global cannabis and psychedelics industries, PSYCH exists to stimulate meaningful change in modern healthcare through trusted market intelligence.

For more information, please visit the [PSYCH Investor Summit: Europe & Asia](#) website.

For Media Enquiries:

Katie Smitten

Head of Communications

+34 633 663 699

katie@prohibitionpartners.com

For Event and Sponsorship Enquiries:

Matt Freemantle

Event and Sponsorship Lead

+34 645 116 528

matt@prohibitionpartners.com

For PSYCH Enquiries:

Victoria Dekker

Head of Growth

+1 (506) 962-6565

victoria@prohibitionpartners.com

